Literature DB >> 20225396

Glucagon-like peptide-1 receptor signalling selectively regulates murine lymphocyte proliferation and maintenance of peripheral regulatory T cells.

I Hadjiyanni1, K A Siminovitch, J S Danska, D J Drucker.   

Abstract

AIMS/HYPOTHESIS: Glucagon-like peptide-1 receptor (GLP-1R) agonists improve glucose control in animals and humans with type 1 diabetes. However, there is little information on the role of the GLP-1R in the immune system. We studied the role of the GLP-1R in immune function in wild-type (WT) and nonobese diabetic (NOD) and Glp1r-/- mice.
METHODS: Glp1r mRNA expression was examined in sorted immune subpopulations by RT-PCR. The effects of GLP-1R activation were assessed on cAMP production and proliferation, migration and survival of primary immune cells from WT and NOD mice. The ability of primary cells from Glp1r-/- mice to proliferate, migrate or survive apoptosis was determined. Immunophenotyping studies were performed to assess the frequency of immune subpopulations in Glp1r-/- mice.
RESULTS: Ex vivo activation of the GLP-1R resulted in a modest but significant elevation of cAMP in primary thymocytes and splenocytes from both WT and NOD mice. GLP-1R activation did not increase proliferation of primary thymocytes, splenocytes or peripheral lymph node cells. In contrast, Glp1r-/- thymocytes exhibited a hypoproliferative response, whilst peripheral Glp1r-/- lymphocytes were hyperproliferative in response to mitogenic stimulation. Activation or loss of GLP-1R signalling did not modify apoptosis or chemotaxis in primary lymphocytes. Male Glp1r-/- mice exhibited a significantly lower percentage of peripheral regulatory T cells, although no differences were observed in the numbers of CD4+ and CD8+ T cells and B cells in the spleen and lymph nodes of Glp1r-/- mice. CONCLUSIONS/
INTERPRETATION: These studies establish that GLP-1R signalling may regulate lymphocyte proliferation and maintenance of peripheral regulatory T cells.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20225396     DOI: 10.1007/s00125-009-1643-x

Source DB:  PubMed          Journal:  Diabetologia        ISSN: 0012-186X            Impact factor:   10.122


  51 in total

Review 1.  Calcium signaling mechanisms in T lymphocytes.

Authors:  R S Lewis
Journal:  Annu Rev Immunol       Date:  2001       Impact factor: 28.527

2.  Rise and fall of cyclic AMP required for onset of lymphocyte DNA synthesis.

Authors:  T Wang; J R Sheppard; J E Foker
Journal:  Science       Date:  1978-07-14       Impact factor: 47.728

3.  Tissue distribution of messenger ribonucleic acid encoding the rat glucagon-like peptide-1 receptor.

Authors:  B P Bullock; R S Heller; J F Habener
Journal:  Endocrinology       Date:  1996-07       Impact factor: 4.736

4.  Human CD4+ T lymphocytes with increased intracellular cAMP levels exert regulatory functions by releasing extracellular cAMP.

Authors:  Silvia Vendetti; Mario Patrizio; Antonella Riccomi; Maria Teresa De Magistris
Journal:  J Leukoc Biol       Date:  2006-08-03       Impact factor: 4.962

5.  Sex-specific effect of insulin-dependent diabetes 4 on regulation of diabetes pathogenesis in the nonobese diabetic mouse.

Authors:  Evgueni A Ivakine; Casey J Fox; Andrew D Paterson; Steven M Mortin-Toth; Angelo Canty; David S Walton; Katarina Aleksa; Shinya Ito; Jayne S Danska
Journal:  J Immunol       Date:  2005-06-01       Impact factor: 5.422

Review 6.  Glycaemic effects of incretins in Type 1 diabetes mellitus: a concise review, with emphasis on studies in humans.

Authors:  John Dupre
Journal:  Regul Pept       Date:  2005-06-15

7.  Exendin-4 treatment expands graft beta-cell mass in diabetic mice transplanted with a marginal number of fresh islets.

Authors:  Jyuhn-Huarng Juang; Chien-Hung Kuo; Chun-Hsing Wu; Charity Juang
Journal:  Cell Transplant       Date:  2008       Impact factor: 4.064

8.  Exendin-4 treatment of nonobese diabetic mice increases beta-cell proliferation and fractional insulin reactive area.

Authors:  Song Xue; Clive Wasserfall; Matthew Parker; Sean McGrail; Kieran McGrail; Martha Campbell-Thompson; Desmond A Schatz; Mark A Atkinson; Michael J Haller
Journal:  J Diabetes Complications       Date:  2009-02-13       Impact factor: 2.852

9.  Enhanced glucose-dependent insulinotropic polypeptide secretion and insulinotropic action in glucagon-like peptide 1 receptor -/- mice.

Authors:  R A Pederson; M Satkunarajah; C H McIntosh; L A Scrocchi; D Flamez; F Schuit; D J Drucker; M B Wheeler
Journal:  Diabetes       Date:  1998-07       Impact factor: 9.461

10.  Protection and reversal of excitotoxic neuronal damage by glucagon-like peptide-1 and exendin-4.

Authors:  TracyAnn Perry; Norman J Haughey; Mark P Mattson; Josephine M Egan; Nigel H Greig
Journal:  J Pharmacol Exp Ther       Date:  2002-09       Impact factor: 4.030

View more
  50 in total

1.  Novel candidate colorectal cancer biomarkers identified by methylation microarray-based scanning.

Authors:  Yuriko Mori; Alexandru V Olaru; Yulan Cheng; Rachana Agarwal; Jian Yang; Delgermaa Luvsanjav; Wayne Yu; Florin M Selaru; Susan Hutfless; Mark Lazarev; John H Kwon; Steven R Brant; Michael R Marohn; David F Hutcheon; Mark D Duncan; Ajay Goel; Stephen J Meltzer
Journal:  Endocr Relat Cancer       Date:  2011-07-04       Impact factor: 5.678

2.  Essay for the 2011 CIHR/CMAJ award: glucagon-like peptides for metabolic and gastrointestinal disorders.

Authors:  Daniel J Drucker
Journal:  CMAJ       Date:  2012-01-23       Impact factor: 8.262

Review 3.  Glucagon-Like Peptide-1 and Its Class B G Protein-Coupled Receptors: A Long March to Therapeutic Successes.

Authors:  Chris de Graaf; Dan Donnelly; Denise Wootten; Jesper Lau; Patrick M Sexton; Laurence J Miller; Jung-Mo Ahn; Jiayu Liao; Madeleine M Fletcher; Dehua Yang; Alastair J H Brown; Caihong Zhou; Jiejie Deng; Ming-Wei Wang
Journal:  Pharmacol Rev       Date:  2016-10       Impact factor: 25.468

4.  MARCKS phosphorylation and amylase release in GLP-1-stimulated acini isolated from rat pancreas.

Authors:  Keitaro Satoh; Motoshi Ouchi; Asuka Morita; Masanori Kashimata
Journal:  J Physiol Sci       Date:  2018-05-29       Impact factor: 2.781

5.  GLP-1 receptor is expressed in human stomach mucosa: analysis of its cellular association and distribution within gastric glands.

Authors:  Efrat Broide; Olga Bloch; Gilad Ben-Yehudah; Dror Cantrell; Haim Shirin; Micha J Rapoport
Journal:  J Histochem Cytochem       Date:  2013-06-26       Impact factor: 2.479

Review 6.  Is there a role for the incretin system in blood pressure regulation?

Authors:  Akhilesh Rao; Ravi Nistala
Journal:  Curr Hypertens Rep       Date:  2014-03       Impact factor: 5.369

Review 7.  Incretins and selective renal sodium-glucose co-transporter 2 inhibitors in hypertension and coronary heart disease.

Authors:  Ramiro A Sanchez; Hugo Sanabria; Cecilia de Los Santos; Agustin J Ramirez
Journal:  World J Diabetes       Date:  2015-09-10

8.  Incretin mimetics as pharmacologic tools to elucidate and as a new drug strategy to treat traumatic brain injury.

Authors:  Nigel H Greig; David Tweedie; Lital Rachmany; Yazhou Li; Vardit Rubovitch; Shaul Schreiber; Yung-Hsiao Chiang; Barry J Hoffer; Jonathan Miller; Debomoy K Lahiri; Kumar Sambamurti; Robert E Becker; Chaim G Pick
Journal:  Alzheimers Dement       Date:  2014-02       Impact factor: 21.566

Review 9.  Incretin drugs in diabetic kidney disease: biological mechanisms and clinical evidence.

Authors:  Radica Z Alicic; Emily J Cox; Joshua J Neumiller; Katherine R Tuttle
Journal:  Nat Rev Nephrol       Date:  2020-11-20       Impact factor: 28.314

10.  Sitagliptin (MK0431) inhibition of dipeptidyl peptidase IV decreases nonobese diabetic mouse CD4+ T-cell migration through incretin-dependent and -independent pathways.

Authors:  Su-Jin Kim; Cuilan Nian; Christopher H S McIntosh
Journal:  Diabetes       Date:  2010-04-05       Impact factor: 9.461

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.